Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone Solution and Dexamethasone in Mucolox™

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and older.~* Patients with symptomatic biopsy proven Oral Inflammatory Ulcerative Diseases (worst VAS sensitivity score ≥ 7 over the last week).~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Patients already on topical or systemic steroids.~* Inability to comply with study instructions.~* Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.~* VAS sensitivity score \< 7.~* Pregnant women. A urine pregnancy test will be performed for women of child bearing potential.~* Allergy to fluconazole.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- dexamethasone 0.5mg/5ml solution in Mucolox™ (group A) (Type: EXPERIMENTAL): Dexamethasone solution (0.5mg/5ml) in Mucolox™ three times a day (TID) swish and spit for 4 weeks
- dexamethasone 0.5mg/5ml solution (Arm B) (Type: ACTIVE_COMPARATOR): Dexamethasone solution (0.5mg/5ml) TID swish and spit for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).